Pablo J. Cagnoni

Insider Reports History

Entity
Individual
Location
Onyx Pharmaceuticals, Inc., 249 E. Grand Ave., South San Francisco, CA
Signature
/s/ Elizabeth Feeney, Attorney-In-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Pablo J. Cagnoni:

Stock Role Class Num Shares Value Price $ Report Date Ownership
INCYTE CORP President, R&D Common Stock 221K $14.2M $64.25 Jul 15, 2024 Direct
Rubius Therapeutics, Inc. Director Restricted Stock Units 75K Jan 31, 2023 Direct
Rubius Therapeutics, Inc. Director Common Stock 66.1K Feb 1, 2023 Direct
INCYTE CORP President, R&D Employee Stock Option (right to buy) 44.4K Jul 15, 2024 Direct
Fusion Pharmaceuticals Inc. Director Stock Option (Right to Buy) 0 Jun 4, 2024 Direct

Insider Reports Filed by Pablo J. Cagnoni

Symbol Company Period Transactions Value $ Form Type Date Filed Role
INCY INCYTE CORP Jul 15, 2024 3 -$48.1K 4 Jul 17, 2024 President, R&D
FUSN Fusion Pharmaceuticals Inc. Jun 4, 2024 5 $0 4 Jun 4, 2024 Director
INCY INCYTE CORP Jan 18, 2024 1 $0 4 Jan 22, 2024 President, R&D
INCY INCYTE CORP Jul 14, 2023 2 $0 4 Jul 18, 2023 President, R&D
FUSN Fusion Pharmaceuticals Inc. Jun 14, 2023 1 $0 4 Jun 14, 2023 Director
INCY INCYTE CORP Jun 7, 2023 0 $0 3 Jun 7, 2023 President, R&D
INCY INCYTE CORP Jun 5, 2023 1 $0 4/A Jun 21, 2023 President, R&D
RUBY Rubius Therapeutics, Inc. Feb 1, 2023 1 -$2.11K 4 Feb 1, 2023 Director
RUBY Rubius Therapeutics, Inc. Jan 29, 2023 5 -$1.74K 4 Jan 31, 2023 Director
FUSN Fusion Pharmaceuticals Inc. Jun 14, 2022 1 $0 4 Jun 22, 2022 Director
RUBY Rubius Therapeutics, Inc. Jan 29, 2022 5 -$44.2K 4 Feb 1, 2022 CEO and President, Director
RUBY Rubius Therapeutics, Inc. Dec 31, 2021 2 $0 5 Feb 14, 2022 CEO and President, Director
FUSN Fusion Pharmaceuticals Inc. Jun 4, 2021 1 $0 4 Jun 7, 2021 Director